| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.0062 | 0.9 |